Advances in glaucoma treatment and management: Outflow drugs

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 5, 2012, Pages 2495-2500

  Kaufman, Paul L ^a   Rasmussen, Carol A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ACTIN; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA CATENIN; BETA1 INTEGRIN; BOL303259X; CALDESMON; CALYCULIN A; COCHLIN; CS 088; CYCLOHEXYLADENOSINE; ENALAPRILAT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INO 8875; KAPPA OPIATE RECEPTOR; MATRIX METALLOPROTEINASE; NITRIC OXIDE; OPA 6566; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN F2 ALPHA; PROSTANOID RECEPTOR; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VIRUS VECTOR; VITRONECTIN RECEPTOR; WNT PROTEIN;

ARTICLE; CELL ENCAPSULATION; CILIARY MUSCLE; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LYMPH VESSEL; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RNA INTERFERENCE; SCHLEMM CANAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TRABECULAR MESHWORK; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CILIARY BODY; DRUG DELIVERY SYSTEMS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MOLECULAR TARGETED THERAPY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; SCLERA; TRABECULAR MESHWORK;

EID: 84860621730     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9483m     Document Type: Article

References (31)

1. Stamer WD, Lei Y, Boussommier-Calleja A, Overby DR, Ethier CR. eNOS, a pressure-dependent regulator of intraocular pressure. Invest Ophthalmol Vis Sci. 2011;52:9438-9444.
2. Ethier CR, Kamm RD, Palaszewski BA, Johnson MC, Richardson TM. Calculations of flow resistance in the juxtacanalicular mesh-work. Invest Ophthalmol Vis Sci. 1986;27:1741-1750.
3. Junglas B, Yu AHL, Welge-Lussen U, Tamm ER, Fuchshofer R. Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells Exp Eye Res. 2009; 88:1065-1075.
4. Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects, Exp Eye Res. 2009,88:648-655.
5. Kaufman PL, Barany EH. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest Ophthalmol. 1976;15(10):793-807.
6. Kaufman PL. Enhancing trabecular outflow by disrupting the actin cytoskeleton, increasing uveoscleral outflow with prostaglandins, and understanding the pathophysiology of presbyopia interrogating Mother Nature: asking why, asking how, recognizing the signs, following the trail. Exp Eye Res. 2008;86:3-17.
7. Fautsch MP, Johnson DH. Aqueous humor outflow: what do we know?-where will it lead us? Invest Ophthalmol Vis Sci. 2006; 47(10):4181-4187.
8. Clark AF, Brotchie D, Read AT, et al. Dexamethasone alters F-actin architecture and promotes cross-linked actin network formation in human trabecular meshwork tissue. Cell Motil Cytoskel. 2005;60: 83-95.
9. Filla MS, Schwinn MK, Sheibani N, Kaufman PL, Peters DM. Regulation of cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells by convergence of distinct beta1 and beta3 integrin pathways.) Invest Ophthalmol Vis Sci. 2009; 50(12):5723-5731.
10. Bhattacharya SK, Gabelt BT, Ruiz J, Picciani R, Kaufman PL. Coch-lin expression in anterior segment organ culture models after TGFbeta2 treatment. Invest Ophthalmol Vis Sci. 2009;50(2):551-559.
11. Lee ES, Gabelt BT, Faralli JA, et al. COCH transgene expression in cultured human trabecular meshwork cells and its effect on outflow facility in monkey organ cultured anterior segments. Invest Ophthalmol Vis Sci. 2010;51(4):2060-2066.
12. Krauss AH, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2a agonist, in preclinical models. Exp Eye Res. 2011;93:250-255
13. Woodward DF, Nilsson SF, Toris CB, Kharlamb AB, Nieves AL, Krauss AH. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. Invest Ophthalmol Vis Sci. 2009;50:3320-3328.
14. Millard LH, Woodward DF, Stamer WD. The role of the prostaglandin EP4 receptor in the regulation of human outflow facility. Invest Ophthalmol Vis Sci. 2011;52(6):3506-3513
15. Yucel YH, Johnston MG, Ly T, et al. Identification of lymphatics in the ciliary body of the human eye: a novel "uveolymphatic" outflow pathway. Exp Eye Res. 2009;89(5):810-819
16. Mao W, Wordinger RJ, Clark AF. Focus on molecules: SFRP1. Exp Eye Res. 2010;91:552-553
17. Wang W-H, McNatt LG, Pang I-H, et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest. 2008;118(3):1056-1064.
18. Daines BS, Kent AR, McAleer MS, Crosson CE. Intraocular adenosine levels in normal and ocular-hypertensive patients. J Ocul Pharmacol Ther. 2003;19:113
19. Tian B, Gabelt BT, Crosson CE, Kaufman PL. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res. 1997;64:979-989.
20. Crosson CE, Sloan CF, Yates PW. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenos-ine. Invest Ophthalmol Vis Sci. 2005;46:3795-3799
21. Kaufman PL, Barany EH. Adrenergic drug effects on aqueous outflow facility following ciliary muscle retrodisplacement in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 1981;20(5):644-651.
22. Wang R-F, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2005;80:629-632.
23. Inoue T, Yokoyoma T, Mori Y, Sasaki Y, Hosokawa T, Yanagisawa H, Koike H. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits. Curr Eye Res. 2001;23:133-138.
24. Inoue T, Yokoyoma T, Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits. Curr Eye Res. 2001;23:139-143.
25. Lotti VJ, Pawlowski N. Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys. J Ocul Pharmacol. 1990; 6(1):1-7.
26. Schneemann A, Leusink-Muis A, van den Berg T, Hoyng PF, Kam-phuis W. Elevation of nitric oxide production in human trabecular meshwork by increased pressure. Graefes Arch Clin Exp Ophthalmol. 2003;241(4):321-326.
27. Russell-Randall KR, Dortch-Carnes J. Kappa opioid receptor localization and coupling to nitric oxide production in cells of the anterior chamber. Invest Ophthalmol Vis Sci. 2011;52(8):5233-5239.
28. Spiga MG, Borrás T. Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma. Invest Ophthalmol Vis Sci. 2010;51(6):3029-3041.
29. Buie LK, Rasmussen CA, Porterfield EC, et al. Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabec-ular meshwork of living rats and monkeys. Invest Ophthalmol Vis Sci. 2010;51(1):236-248.
30. Barraza RA, Rasmussen CA, Loewen N, et al. Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of nonhuman primates. Hum Gene Ther. 2009;20(3): 191-200.
31. Medeiros FA, Weinreb RN, Zangwill LM, et al. Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology. 2008;115(6):934-940.